pocketful logo
Mankind Pharma Ltd logo

Mankind Pharma Ltd

NSE: MANKIND BSE: 543904

₹2240.10

(0.11%)

Wed, 18 Mar 2026, 08:21 pm

Mankind Pharma EV/EBITDA Ratio

Particulars201920202021202220232024
Price to earnings ratio000048.1849.26
Price to book ratio00009.836.98
Price to sales ratio00008.988.03
Price to cash flow ratio000042.5341.12
Enterprise value0000891.26B1040B
Enterprise value to EBITDA ratio000034.8133.63
Debt to equity ratio0.040.050.140.020.020.59
Return on equity %030.8426.3618.8622.7616.77

Mankind Pharma Ltd Enterprise Value to EBITDA Ratio

The Mankind Pharma Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Mankind Pharma Ltd's valuation, profitability, and overall financial performance. Tracking the Mankind Pharma Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Mankind Pharma Ltd (NSE: MANKIND, BSE: 543904) is currently trading at ₹2240.10, with a market capitalization of ₹923.78B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Mankind Pharma Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.

Mankind Pharma Ltd Enterprise Value to EBITDA Ratio Current Value

The current Mankind Pharma Ltd Enterprise Value to EBITDA Ratio stands at 33.63.

The Mankind Pharma Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.

Mankind Pharma Ltd Enterprise Value to EBITDA Ratio Historical Trend

The Mankind Pharma Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:

  • 2024: 33.63
  • 2023: 34.81
  • 2022: 0
  • 2021: 0
  • 2020: 0

The decline in Mankind Pharma Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.

What Mankind Pharma Ltd Enterprise Value to EBITDA Ratio Indicates for Investors

The Mankind Pharma Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.

This ratio is an important metric used in fundamental analysis of Mankind Pharma Ltd.

Mankind Pharma Ltd Enterprise Value to EBITDA Ratio Analysis Summary

The Mankind Pharma Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Mankind Pharma Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Mankind Pharma Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800